Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CELC Celcuity Inc
- Stocks
- Healthcare
- NASDAQ: CELC
Price (delayed)
$12.46
Market cap
$471.81M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.05
Enterprise value
$554.05M
Celcuity is a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity's 3rd generation diagnostic platform, CELsignia,
Highlights
The debt has soared by 160% YoY
CELC's net income has plunged by 73% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of CELC
Market
Valuations
Earnings
Shares outstanding
37.87M
Market cap
$471.81M
Enterprise value
$554.05M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.44
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$126.91M
Net income
-$127.16M
EBIT
-$115.1M
EBITDA
-$114.96M
Free cash flow
-$102.47M
Per share
Balance sheet
Liquidity
EPS
-$3.05
EPS diluted
-$3.05
Free cash flow per share
-$2.38
Book value per share
$2.29
Revenue per share
$0
TBVPS
$5.07
Total assets
$218.13M
Total liabilities
$131.46M
Debt
$98.71M
Equity
$86.67M
Working capital
$184.68M
Debt to equity
1.14
Current ratio
6.61
Quick ratio
6.25
Net debt/EBITDA
-0.72
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-49.4%
Return on equity
-96.2%
Return on invested capital
-37.5%
Return on capital employed
-62.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CELC stock price
How has the Celcuity stock price performed over time
Intraday
2.89%
1 week
-3.49%
1 month
17.44%
1 year
-17.1%
YTD
-4.81%
QTD
23.24%
Financial performance
How have Celcuity's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$126.91M
Net income
-$127.16M
Gross margin
N/A
Net margin
N/A
CELC's net income has plunged by 73% YoY and by 14% from the previous quarter
The operating income has dropped by 67% year-on-year and by 12% since the previous quarter
Price vs fundamentals
How does CELC's price correlate with its fundamentals
Growth
What is Celcuity's growth rate over time
Valuation
What is Celcuity stock price valuation
P/E
N/A
P/B
5.44
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 10% YoY and by 8% QoQ
CELC's price to book (P/B) is 43% more than its last 4 quarters average of 3.8 and 39% more than its 5-year quarterly average of 3.9
The equity has contracted by 35% YoY and by 25% from the previous quarter
Efficiency
How efficient is Celcuity business performance
The ROE has plunged by 56% YoY and by 24% from the previous quarter
The return on assets has declined by 14% year-on-year and by 10% since the previous quarter
Celcuity's return on invested capital has increased by 10% YoY but it has decreased by 5% QoQ
Dividends
What is CELC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CELC.
Financial health
How did Celcuity financials performed over time
Celcuity's total assets is 66% more than its total liabilities
CELC's total liabilities has surged by 141% year-on-year
The quick ratio has declined by 41% year-on-year and by 16% since the previous quarter
The debt is 14% more than the equity
The debt has soared by 160% YoY
The equity has contracted by 35% YoY and by 25% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.